Seaweed-Derived Fucoidan Demonstrates Clinically Significant Relief of BPH Symptoms in Randomized Trial
Key Insights
A randomized, double-blind, placebo-controlled trial of 88 men with moderate BPH found that daily high-purity fucoidan supplementation produced clinically significant improvements in overall symptoms over 90 days.
Participants taking fucoidan experienced a more than nine-fold improvement in voiding symptoms and a two-fold improvement in storage symptoms compared to placebo, as measured by the IPSS.
Quality-of-life related to urinary symptoms also improved significantly, with the seaweed-derived compound demonstrating a favorable safety profile throughout the study period.
A randomized, double-blind, placebo-controlled clinical trial conducted by Australian biotechnology company Marinova (search) has demonstrated that a high-purity extract derived from brown seaweed can significantly relieve the symptoms of benign prostatic hyperplasia (search) (BPH), a condition affecting the majority of aging men worldwide.
The 90-day study, published in the journal Research and Reports in Urology, evaluated the effects of fucoidan—a naturally occurring compound found in brown seaweed—in 88 men aged between 45 and 80 years with moderate BPH. Participants were randomized to receive either a daily fucoidan supplement or a placebo.
BPH represents a substantial global health burden, with worldwide prevalence estimates placing the condition at 50–60% of men in their 60s, rising to 90% of men in their 80s. Although typically not life-threatening, the associated urinary symptoms—including difficulty passing urine, a weak stream, and increased urinary frequency—often result in a significant reduction in quality-of-life.
Rationale and Study Design
Lead researcher Dr. Barbara Wimmer highlighted the unmet need that drove the investigation. "To date, very few natural compounds have been clinically studied and shown to support prostate health effectively," Dr. Wimmer said. "The documented bioactivities of fucoidan led us to embark on this groundbreaking trial."
The study employed the widely recognized International Prostate Symptom Score (IPSS) to assess changes in BPH symptoms, providing a validated and standardized measure of both voiding and storage symptom domains.
Clinically Meaningful Symptom Improvements
Compared to the placebo group, participants receiving the high-purity fucoidan supplement demonstrated clinically significant improvements in overall BPH symptoms. The magnitude of benefit was particularly pronounced in voiding symptoms—encompassing emptying, intermittency, weak stream, and straining—where a more than nine-fold improvement was observed relative to placebo.
Storage symptoms, which include urinary frequency, urgency, and nocturia, showed a two-fold improvement in the fucoidan group. Additionally, participants reported a significant improvement in quality-of-life attributable to urinary symptoms.
Safety and Commercial Outlook
Dr. Wimmer emphasized the translational significance of the findings, noting that "the trial results were clinically significant and the fucoidan was shown to be safe throughout the study period." She added, "We expect these findings will result in the commercialisation of high purity fucoidan to help relieve the symptoms of benign prostatic hyperplasia (search)."
Marinova (search), headquartered in Hobart, Australia, specializes in the research, development, and manufacture of high-purity fucoidans for applications spanning nutritional supplements, medical devices, skincare, and pharmaceuticals. The positive results from this trial position the company to advance fucoidan toward broader commercial availability as a natural intervention for prostate health.